drugset
drugset / Trial / NCT01672008

NOX-100 for Preventing Hypotension During Hemodialysis

NCT01672008 ↗

Phase 2 Completed 62 enrolled Medinox, Inc. Orient Europharma Co., Ltd. · collab
RandomizedCrossoverDouble-blindTreatment

Summary

This study is designed to evaluate the safety, tolerability and efficacy profile of NOX-100 to reduce intradialytic hypotension (IDH) in patients undergoing chronic hemodialysis (HD).

Timeline

Start
2012-08
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject NOX-100 Small molecule 0.4 mg/kg —
Subject NOX-100 Small molecule 1.2 mg/kg —
Subject NOX-100 Small molecule 2.5 mg/kg —
Subject NOX-100 Small molecule 5 mg/kg —
Subject NOX-100 Small molecule 10 mg/kg —

Indications

hypotensive disorder